CTOs on the Move

Elcelyx Therapeutics

www.elcelyx.com

 
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.elcelyx.com
  • 11995 El Camino Real Suite 305
    San Diego, CA USA 92130-2567
  • Phone: 858.876.1814

Executives

Name Title Contact Details

Funding

Elcelyx Therapeutics raised $40M on 10/01/2015

Similar Companies

iWalk

iWalk is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MD Care

MD Care is a Los Alamitos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Embr Labs

Founded at MIT, the Embr Wave® & Wave 2 are personal cooling bands and heated wearables for fast, natural thermal wellness and thermotherapy.

AppliedVR

AppliedVR is the leader in therapeutic virtual reality, transforming healthcare through the power of pixels. Since its founding in 2015, appliedVR has delivered scientifically designed and validated digital health solutions to over 20,000 patients in more than 250 hospitals and in 8 countries globally.

Heart Force Medical

Heart Force Medical Inc. (HFM), a private company, has invented and has patents pending for the digital Ballistocardiograph (dBG(TM)). The dBG 300, which is already approved in Canada and the United States, captures the movement of the heart during each cardiac cycle (heart beat). This movement (acceleration and force) is sensed by an accelerometer aligned to the three principal axes and displayed on a computer screen using HFM's proprietary software. Preliminary evaluation has determined that a 10-30 second recording of the dBG waveform is sufficient for a detailed analysis of cardiac performance. The Heart Force dBG 300 device is a non-invasive, standalone, portable unit and contains sophisticated digital sensors and proprietary software.